Overview:

Market Research Future (MRFR) in their detailed analysis covers major driving forces that ensure prospects for the market in the foreseeable future. Chief factors that play significant roles are growing awareness regarding the treatment of this disease and widescale availability of the clinical facilities that backs up the market sufficiently.

The neuromuscular disorder can hit anyone anytime. Myasthenia gravis is a form of disorder that affects the skeletal muscles and weakens them. As a result, the patient’s movements get restricted. Primarily it blocks the connection between muscles and nerve cells and creates difficulties in contraction and relaxation of muscles. The most to get affected is the human face especially eyes and eyelids, facial expressions, chewing, and speaking. Young people don’t get affected much, whereas the geriatric population and women are more susceptible to this disease. The myasthenia gravis market is expecting a steady CAGR of 7.5% during the forecast period (2017-2023).

Segmentation:

The global myasthenia gravis disease market can be segmented by diagnosis, treatment, and end-user.

Diagnosis-wise segmentation includes imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. Imaging can be further segmented into X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.

Treatment-based segmentation comprises medication, surgery, autologous Hematopoietic Stem Cell Transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others.

Based on medication, the market can be segmented into acetylcholinesterase inhibitors, immunosuppressant drugs, steroids, and others. The acetylcholinesterase inhibitors are classified into atropine, neostigmine, pyridostigmine, and others. Immunosuppressant drugs can be sub-segmented into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids are further segmented into prednisone and others. Surgery includes thymectomy and others.

On the basis of end-user, the market can be segmented into hospitals, clinics, academic research institutes, and others.

Regional Analysis:

Region-specific segmentation includes the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).

The Americas, riding on the revenue generated by various pharmaceutical companies, have emerged as the market bellwether. Government funding in the area of research in rising simultaneously with the growing awareness. The U.S. holds the major portion of the regional market.

The European market comes next driven by the same reasons. The APAC is expecting the fastest growth rate as the region has a huge patient pool who are suffering from the disease. Healthcare reforms in emerging economies such as India and China are boosting the market significantly. The MEA is also investing much in research and development (RD) owing to which the region can prosper substantially.

Competition Scenario:

Major market influencers are investing significantly in RD to have a better command over the market. Innovations are seeing the light of the day which is assisting the market to take a forward leap.

Some of the key players in the global myasthenia gravis disease market are Valeant Pharmaceuticals International (U.S.), Sun Pharmaceuticals Industries Ltd. (India), Piramal Healthcare (India), Novartis Pharmaceuticals Corporation (Switzerland), Apotex Corporation (Canada), Teva Pharmaceutical Industries Ltd. (Israel), RPG Life Sciences (India), Cipla (India), F. Hoffmann Roche La Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Biogen Inc. (U.S.), and AbbVie Inc. (U.S.), GlaxoSmithKline plc (UK), Fresenius Kabi (Germany), and others.